rituximab-abbs Truxima
Selected indexed studies
- Truxima (rituximab-abbs) for Periocular Xanthogranuloma with Adult-Onset Asthma and Systemic IgG4-Related Disease. (Ophthalmic Plast Reconstr Surg, 2023) [PMID:37195834]
- Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. (BioDrugs, 2024) [PMID:38935234]
- Rituximab. (, 2006) [PMID:30000857]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Truxima (rituximab-abbs) for Periocular Xanthogranuloma with Adult-Onset Asthma and Systemic IgG4-Related Disease. (2023) pubmed
- Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. (2024) pubmed
- Rituximab. (2006) pubmed
- Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study. (2021) pubmed
- Uptake of rituximab biosimilars in Medicare and Medicaid in 2019-2022. (2024) pubmed
- Rituximab reference vs biosimilar utilization for oncology vs nononcology indications. (2023) pubmed
- Increasing Biosimilar Uptake in Rheumatology Clinics Within a Large Academic Medical Center. (2025) pubmed
- The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know. (2019) pubmed
- Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. (2021) pubmed